Medtech IPO Environment Cools With Sluggish Q1
This article was originally published in Clinica
If the first quarter’s IPO activity levels are anything to go by, it looks like medtech companies may be facing a cooler public fundraising climate in 2016.
You may also be interested in...
After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.